Potential of Inducible Nitric Oxide Synthase as a Therapeutic Target for Allergen-Induced Airway Hyperresponsiveness : A Critical Connection to Nitric Oxide Levels and PARP Activity. by S. Ibba et al.
Research Article
Potential of Inducible Nitric Oxide Synthase as a Therapeutic
Target for Allergen-Induced Airway Hyperresponsiveness:
A Critical Connection to Nitric Oxide Levels and PARP Activity
Salome’ V. Ibba,1,2 Mohamed A. Ghonim,1,3 Kusma Pyakurel,1 Matthew R. Lammi,4
Anil Mishra,5 and A. Hamid Boulares1
1The Stanley Scott Cancer Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
2Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
3Microbiology and Immunology Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt
4Pulmonary/Critical Care and Allergy/Immunology Section, School of Medicine, Louisiana State University,
New Orleans, LA 70112, USA
5Eosinophilic Disorder Center in the Section of Pulmonary Diseases, Tulane University School of Medicine,
New Orleans, LA 70112, USA
Correspondence should be addressed to A. Hamid Boulares; hboulr@lsuhsc.edu
Received 5 February 2016; Revised 11 May 2016; Accepted 22 May 2016
Academic Editor: Alex Kleinjan
Copyright © 2016 Salome’ V. Ibba et al.This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Although expression of inducible NO synthase (iNOS) in the lungs of asthmatics and associated nitrosative damage are established,
iNOS failed as a therapeutic target for blocking airway hyperresponsiveness (AHR) and inflammation in asthmatics.This dichotomy
calls for better strategieswithwhich the enzyme is adequately targeted.Here, we confirm iNOS expression in the asthmatic lungwith
concomitant protein nitration and poly(ADP-ribose) polymerase (PARP) activation.We show, for the first time, that iNOS is highly
expressed in peripheral blood mononuclear cells (PBMCs) of asthmatics with uncontrolled disease, which did not correspond to
protein nitration. Selective iNOS inhibition with L-NIL protected against AHR upon acute, but not chronic, exposure to ovalbumin
or house dust mite (HDM) in mice. Supplementation of NO by nitrite administration significantly blocked AHR in chronically
HDM-exposed mice that were treated with L-NIL. Protection against chronic HDM exposure-induced AHR by olaparib-mediated
PARP inhibitionmay be associatedwith the partial but not the complete blockade of iNOS expression. Indeed, L-NIL administration
prevented olaparib-mediated protection against AHR in chronically HDM-exposed mice. Our study suggests that the amount of
iNOS and NO are critical determinants in the modulation of AHR by selective iNOS inhibitors and renews the potential of iNOS
as a therapeutic target for asthma.
1. Introduction
Asthma is a chronic disease characterized by airway inflam-
mation and hyperresponsiveness (AHR), overproduction of
mucus, and airway and vascular wall remodeling [1–4].
These manifestations lead to repeated periods of shortness of
breath, wheezing, and chest tightness whichmay incapacitate
affected individuals.The incidence of the disease is increasing
at an alarming rate affecting 1 in 10 children and 1 in 12
adults with a total of 300 million worldwide [5]. Worldwide,
deaths from asthma have reached over 250,000 annually.
Asthma can be controlled by a combination of an inhaled
corticosteroid (anti-inflammatory) and a short- or long-
acting 𝛽2-adrenergic agonist. However, a sizable portion
of these patients (∼10%) do not respond to the available
therapies [5, 6]. Thus, new therapies that target all or some
of the symptoms of asthma are urgently needed.
An increasing number of conflicting reports have demon-
strated detrimental, protective, and sometimes neutral roles
for inducible NO synthase (iNOS) in the pathogenesis of
asthma [7, 8]. However, it is undoubtedly established that
iNOS is expressed in lungs of asthmatics with a subsequent
Hindawi Publishing Corporation
Mediators of Inﬂammation
Volume 2016, Article ID 1984703, 10 pages
http://dx.doi.org/10.1155/2016/1984703
2 Mediators of Inflammation
production of NO and generation of the reactive metabolite
ONOO− [9–12]. It appears that expression of iNOS is even
higher in sputum cells from asthmatics compared to those
from patients with controlled disease or healthy individuals
[13].Thus, inhibition of iNOS appears to be a very viable ther-
apeutic target to prevent manifestation of asthma symptoms
upon exposure to allergens [14–16]. This potential has been
challenged by the observation that a selective iNOS inhibitor
did not affect airway inflammatory cell numbers or AHR
after allergen challenge in steroid-na¨ıve human asthmatics
[17]. However, it is difficult to ignore the fact that asthma
protection and susceptibility are associated with polymor-
phisms in the iNOS gene [18]. We recently showed that iNOS
gene deletionwas associated with a reduction in eosinophilia,
mucus hypersecretion, andTh2 cytokine production upon an
acute exposure to ovalbumin (OVA) [19]. Such protectionwas
completely abolished upon a chronic exposure to the allergen.
Interestingly, pulmonary fibrosis observed in wild type mice
under the chronic protocol was completely absent in iNOS−/−
mice despite persistent IL-5 and IL-13 production. The pub-
lished results exemplified the complexity of the role of iNOS
in asthma and the preservation of its potential as a therapeutic
target. We also showed that poly(ADP-ribose) polymerase-
(PARP-) 1 is required for iNOS expression [20] and that PARP
inhibition protects against AHR upon an acute or chronic
exposure to allergens [21, 22]. Overall, we believe that it is
premature to conclude that targeting iNOS in asthma is futile
and that more studies should be geared toward exploring
new avenues to take advantage of such an important clinical
target. Accordingly, the goal of the present study was to
examine whether pharmacological inhibition of iNOS could
be manipulated to provide protection against AHR upon
chronic OVA or house dust mite extracts (HDM) exposure
and whether the protection conferred by PARP inhibition
was related to its control of iNOS expression level. L-N6-
(1-Iminoethyl)lysine dihydrochloride (L-NIL) and AZD2281
(olaparib), two clinically tested iNOS and PARP inhibitors,
respectively, were used to conduct the following study.
2. Methods
2.1. Human Subjects, Immunohistochemistry, and Immunoblot
Analysis. Five healthy and eight asthmatic individuals were
recruited under a protocol (#8450) approved by institutional
review board of Louisiana State University Health Sciences
Center. Subjects were included in the study if they were ≥18
years of age with a physician diagnosis of asthma. Subjects
were excluded if they were diagnosed with another lung
disease other than asthma, had active malignancy or inflam-
matory condition, or smoked≥10 pack-years. Asthma control
was assessed by the Asthma Control Test (ACT) with a score
≤19 indicating uncontrolled asthma and ≥20 demonstrating
that asthma is well controlled [23]. Human PBMCs isolated
from peripheral blood of donors were subjected to protein
extractions followed by immunoblot analysis with antibodies
to nitrotyrosine (EMD Millipore, Bedford, MA), human
iNOS (Abcam, Cambridge, MA), the poly(ADP-ribose) moi-
ety (PAR) of PARP-modified proteins (ENZO Life Sciences,
Farmingdale, NY), or GAPDH (Abcam). Paraffin-embedded
tissue sections from two deidentified lung specimens from
individuals who died from severe asthma were subjected to
immunohistochemistry with antibodies to PAR, iNOS, or
nitrotyrosine. The sections were then counterstained with
hematoxylin and mounted prior to examination by light
microscopy.
2.2. Animals, OVA and HDM Challenge, and AHR Measure-
ments. Six-week-old to eight-week-old C57BL/6J male mice
were purchased from Jackson Laboratories (Bar Harbor, ME,
USA). C57BL/6 iNOS−/− mice were bred at the LSUHSC
vivarium and allowed unlimited access to sterilized chow and
water. Husbandry, experimental protocols, and procedures
were all approved by the LSUHSC Animal Care and Use
Committee.
Mice were sensitized to chicken (3mg/kg), OVA (Sigma-
Aldrich, St. Louis,MO), or (0.5𝜇g/kg)HDM(Dermatophago-
ides pteronyssinus) extract (Greer Labs, Lenoir, NC). The
challenge protocols with OVA or HDM are outlined in
Supplementary Figure S1 in Supplementary Martial available
online at http://dx.doi.org/10.1155/2016/1984703. Briefly, mice
were challenged with aerosolized 3% OVA for 30min three
times on days 14, 16, and 18 for the acute asthma model or
three times a week for three weeks (chronic asthma model).
Other groups of mice were challenged intranasally with
1.25 𝜇g/kg whole HDM extract on days 24, 25, and 26 for
the acute asthma model or 3 times per week for a total
of 4 weeks for the chronic asthma model. Control groups
were not sensitized or challenged. Additional challenged
groups of mice were administered i.p. 5mg/kg L-N6-(1-
Iminoethyl)lysine dihydrochloride (L-NIL) (Sigma-Aldrich)
and/or olaparib (Selleckchem, Pittsburgh, PA) in saline
30 minutes after each challenge. Some groups of mice
also received i.p. injections of 20 𝜇g/kg of nitrite (NaNO
2
)
(Sigma-Aldrich) as NO source 30min after each challenge.
AHR to inhaled methacholine was measured in unre-
strained, conscious mice 24 h after the last challenge by
recording “enhanced pause” (Penh) by whole body plethys-
mography (EMKA Systems, Falls Church, VA, or DSI Buxco,
St. Paul, MN). In brief, the baseline readings were taken and
averaged for 3min after animals were placed in a barometric
plethysmographic chamber. Normal saline or increasing
concentrations of aerosolized methacholine (Sigma-Aldrich)
(12.5–100mg/mL) were nebulized, and readings were taken
and averaged for 3min after each nebulization and enhanced
pause (Penh) representing AHR was calculated. Mice were
sacrificed 24 h after the last challenge and lungs were sub-
jected to RNA extraction as described below.
2.3. Cell Culture: Real Time PCR. Wild type or PARP-1−/−
mouse embryonic fibroblasts (MEFs) were serum starved for
24 hours and then treated with 1 𝜇g/mL LPS (Sigma-Aldrich)
and 10 ng/mL IFN-𝛾 (RD System Minneapolis, MN) for 6
hours. The collected cells as well as homogenized lungs from
the abovementioned experimental groups were subjected
to RNA extraction using the RNeasy mini kit (QIAGEN,
Valencia, CA). The extracted RNA was reverse-transcribed
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and the resulting cDNA was subjected to quantitative real
time PCR using primer sets (IDT, San Jose, CA, USA)
specific to mouse iNOS (F 5󸀠-GTG TTG CAA GCT GAT
GGT CA-3󸀠 and R 5󸀠-TGT TGT AGC GCT GTG TGT CA-
3󸀠), IL-5 (F 5󸀠-GGGCTTCCTGCTCCTATCTA-3󸀠 and R 5󸀠-
CAGTCATGGCA CAGTCTGAT-3󸀠), or 𝛽-actin (F 5󸀠-TAC
AGC TTC ACC ACC ACA GC-3󸀠 and R 5󸀠-TCT CCA GGG
AGG AAG AGG AT-3󸀠).
2.4. Data Analysis. All data are expressed as means ± SD
of values from at least 5 mice per group. PRISM software
(GraphPad, San Diego, CA, USA) was used to analyze the
differences between experimental groups by t-test or one way
ANOVA followed by Tukey’s multiple comparison tests.
3. Results
3.1. PARP Activation, iNOS Expression, and Protein Nitra-
tion Are Elevated in Lung and PBMCs of Asthmatics. We
recently showed that PARP is activated in lung tissues and
PBMCs of human asthmatics [21]. Figure 1(a) confirms the
activation of PARP in lung tissues by immunohistochemistry
using antibodies to the poly(ADP-ribose) moiety of mod-
ified proteins. The figure also shows that PARP activation
occurred in epithelial and a subpopulation of immune cells.
Figure 1(b) shows that iNOS expression is prominent in
epithelial and endothelial cells and macrophages. Protein
nitration as assessed by IHC with antibodies to nitrotyrosine
appears to be distributed throughout the lung tissue including
the matrix but was more prominent in epithelial cells (Fig-
ure 1(c)).
PBMCs collected from asthmatics or healthy individuals
were subjected to immunoblot analysis with antibodies to
nitrotyrosine, iNOS, orGAPDH. Figure 1(d) shows that iNOS
is highly expressed in PBMCs from asthmatics compared to
cells from healthy individuals. However, the expression of
iNOS did not strictly correspond to protein nitration. Indeed,
some PBMCs exhibited high levels of iNOS but showed
protein nitration levels comparable to those detected in
cells from nonasthmatics. Conversely, PBMCs that exhibited
extensive protein nitration displayed low levels of iNOS.
Interestingly, the two samples (6 and 7) that displayed high
levels of protein nitration were collected from patients whose
asthma was under control according to their ACT score of
21. However, samples from uncontrolled asthma (10 and 12
with ACT scores = 16) displayed levels of protein nitration
comparable to those from nonasthmatics but with high levels
of iNOS. Overall, these results exemplify the known com-
plexity of the relationship between iNOS, protein nitration,
and asthma in humans. Nevertheless, it is noteworthy that the
presence of these factors does not necessarily mean a critical
function in the disease but results from our laboratory and
many others have suggested a potentially direct role for PARP
and iNOS in some or most aspects of asthma.
3.2. Differential Protection of iNOS Inhibition against AHR
Manifestation upon Acute and Chronic Exposure to OVA in
Mice. Our laboratory has shown that iNOS gene deletion
is protective against airway inflammation upon acute, but
not chronic, exposures to OVA [19]. Interestingly, such gene
deletion prevented lung fibrosis in the chronic model of the
disease. Given the potential connection between, and the
coexistence of, lung fibrosis and AHR in chronic asthma
[24], we explored the possibility that administration of L-
NIL, a clinically tested iNOS inhibitor, may be protective
against AHR upon both acute and chronic exposures to
OVA in mice. L-NIL is a selective and long acting inhibitor
of iNOS with IC
50
= 3.3 𝜇M for mouse iNOS [25]. A
clinical trial conducted by Barnes group [14] showed that
administration of 200mg of L-NIL reduced exhaled NO in
patients with mild-to-moderate asthma to levels lower than
those detected in placebo-administered healthy subjects as
early as 30min after administration. Mice were subjected
to the acute or chronic model of asthma as described in
Supplementary Figure S1 followed by an assessment of AHR
using full body plethysmography. Figure 2(a) shows that L-
NIL administration at a dose of 5mg/kg was very effective
in blocking the manifestation of AHR upon acute exposure
to OVA. Surprisingly, however, the protection achieved by
L-NIL administration was completely lost when mice were
chronically exposed toOVA (Figure 2(b)). Similar differential
results were achieved using iNOS−/− mice that were sensi-
tized and acutely (Supplementary Figure S2A) or chronically
(Supplementary Figure S2B) challenged to OVA. The effects
of iNOS inhibition on AHR were similar to the differential
protection conferred by iNOS gene deletion against acute
versus chronic airway inflammation reported by us [19].
3.3. Inhibition of iNOS by L-NIL Failed to Protect against AHR
Induced by a Chronic Exposure to HDM, Which Is Reversed
upon NO Supplementation by Nitrite Administration. Given
the clinical relevance of the present studies and the limitation
of the OVAmodels, we elected to use HDM to induce asthma
in mice due to its characteristic as a major allergen for
humans [21]. To this end, mice were sensitized to HDM and
then subjected to intranasal exposures to the allergen either
acutely constituted by simultaneous daily exposures for 3
days or chronically by challenging the animals three times a
week for four weeks as described in Supplementary Figure
S1. Figure 3(a) shows that, similar to the acute OVA model,
L-NIL administration was extremely efficient in blocking
HDM-induced AHR; in fact, AHR of HDM-treated mice
that received the drug was identical to animals that were
not exposed to HDM. Contrary to the acute HDM exposure
model, iNOS inhibition by L-NIL did not provide a signif-
icant protection against AHR upon a chronic exposure to
HDM. Altogether, the differential effects of iNOS inhibition
on AHR induced by acute or chronic HDM exposure were
very similar to those observed using the acute and chronic
OVAmodels of allergic lung inflammation.These results also
demonstrate that the role of iNOS in AHR manifestation is
not specific to a given model and may be considered as a
general phenomenon.
We next examined whether the failure of iNOS inhi-
bition by L-NIL administration can be reversed by mere
administration of NO source such as nitrite. Figure 3(b)
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Figure 1: PARP activation, iNOS expression, and protein nitration in human asthmatics. Lung sections from a deidentified individual who
died from severe asthma were subjected to immunohistochemistry with antibodies to PAR (a), iNOS (b), nitrotyrosine (c), or (d) control IgG
followed by visualization with light microscopy. Bars: 20𝜇m. The lower panels represent magnifications of the boxed areas. Ed, endothelial
cells; Ep, epithelial cells; Im, immune cells; MQ, macrophages. (e) PBMCs collected from asthmatics with controlled (ACT score ≥ 20) or
uncontrolled (ACT score≤ 19) disease or healthy nonasthmatic (NA) volunteers were subjected to protein extraction followed by immunoblot
analysis with antibodies to human iNOS, nitrotyrosine, or GAPDH.
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Figure 2: Effect of iNOS inhibition by L-NIL on AHR manifestation upon acute or chronic exposure to OVA in mice. C57BL/6 mice were
subjected to OVA sensitization followed by an acute (a) or chronic (b) challenge to aerosolized OVA or left unchallenged. A group of WT
mice were administered i.p. 5mg/kg of the specific iNOS inhibitor (L-NIL) or saline 30min after each OVA challenge. Penhwas recorded 24 h
after the last challenge using a whole body plethysmograph system before and after the indicated concentrations of aerosolized methacholine
(MeCh). Results are plotted as maximal fold increase of Penh relative to baseline (0𝜇MMeCh) and expressed as mean ± SEM, where 𝑛 = 5
mice per group. ∗ ∗ ∗, difference from OVA-challenged mice; 𝑝 ≤ 0.001. ##, difference from control unchallenged mice; 𝑝 ≤ 0.01; ns, no
significant difference.
shows that administration of 20𝜇g/kg nitrite, i.p., 30min after
each challenge with HDM exerted a remarkable protection
against AHR manifestation in response to increasing doses
of methacholine. Concomitantly, nitrite supplementation
decreasedTh2 inflammation as assessed by IL-5mRNA in the
lung (Figure 3(c)). Given the fact that nitrite administration
providesmoderate levels ofNO [26], these results suggest that
NO levels are an important determinant for the protection
against AHR andTh2 inflammation.
3.4. PARP-1 Inhibition-Mediated Protection against AHR in
Chronically HDM-Exposed Mice is Lost upon L-NIL Admin-
istration. We previously demonstrated that PARP inhibition,
genetically or by olaparib, protects against asthma mani-
festation including airway inflammation and AHR [21, 22].
We also showed that PARP-1 regulates iNOS expression in
an animal model of asthma and in cultured cells [20]. The
most fascinating aspect of the connection between PARP-
1 and iNOS is that PARP-1 inhibition does not completely
inhibit expression of iNOS [20] as demonstrated in results
shown in Figure 4(a) using lung fibroblasts isolated from
WT and PARP-1−/− mice and treated with a combination
of LPS and IFN-𝛾. Such incomplete inhibition was also
observed in endothelial cells (data not shown). We thus
hypothesized that the beneficial effect of PARP-1 inhibition
onAHRmay be associatedwith the partial reduction in iNOS
expression, which presumably leads to a production of low-
to-moderate levels of NO. Accordingly, inhibition of iNOS
by L-NIL treatment was predicted to abrogate the protective
effect of PARP inhibition. To test this hypothesis, mice
were chronically exposed to HDM and were administered
a combination of 5mg/kg olaparib and 5mg/kg L-NIL after
each challenge. Figure 4(b) shows that olaparib treatment
provided an excellent protection against AHR, which was
significantly abolished by L-NIL administration. Unlike its
effect on AHR, L-NIL administration only partially reversed
olaparib-mediated protection against Th2 inflammation as
assessed by IL-5 mRNA in lungs (Figure 4(c)). These results
suggest that the low expression of iNOS observed upon
PARP inhibition was protective against both AHR and Th2
inflammation.
4. Discussion
The viability of iNOS as a therapeutic target for the treatment
of asthma was hindered by the contradictory reports of
a number of encouraging animal studies and the negative
results of a clinical trial. The results of the trial showed that
a selective iNOS inhibitor similar to the one used in the
current study provided no protection against AHR or airway
inflammation after allergen challenge in steroid-na¨ıve human
asthmatics [14]. A detailed study from our laboratory showed
that iNOS exerted a differential effect on acute and chronic
asthma [19]. iNOS inhibition was effective in blocking only
acute allergic inflammation but failed to provide any protec-
tion against chronic inflammation [19].The effects on chronic
inflammationwere consistent with those reported by Singh et
al. using a selective iNOS inhibitor (GW274150) [17]. Inter-
estingly, however, iNOS inhibition protected against airway
remodeling potentially by preventing an increase in TIMP-
2 expression [19] despite the persistence of inflammation.
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Figure 3: Effect of iNOS inhibition by L-NIL onAHRmanifestation upon exposure toHDMinmice and the influence ofNO supplementation
by nitrite administration. C57BL/6 mice were subjected to HDM sensitization followed by acute (a) or chronic (b) intranasal challenge with
HDM or were left unchallenged. Challenged mice were administered i.p. 5mg/kg L-NIL with or without 20mg/kg of nitrite (NaNO
2
) as NO
source 30min after each HDM challenge. Penh was recorded 24 h after the last HDM challenge using a whole body plethysmograph before
and after the indicated concentrations of aerosolized MeCh. Results are plotted as maximal fold increase of Penh relative to baseline and
expressed as mean ± SEM, where 𝑛 = 5 mice per group. ∗ and ∗∗, difference from HDM challenged mice with 𝑝 ≤ 0.05 and 𝑃 ≤ 0.01,
respectively; #, difference from control unchallenged mice with 𝑝 < 0.05. RNA isolated from the lungs of the different experimental groups
was reverse-transcribed and the resulting cDNA was subjected to real-time PCR with primer sets specific to mouse IL-5 or 𝛽-actin. Data
is expressed as fold change of values detected in lungs of control mice. ∗∗, difference from control unchallenged mice with 𝑝 = 0.002; ##,
difference from HDM-exposed mice receiving L-NIL with 𝑝 = 0.0031. ns, nonsignificant difference with 𝑝 = 0.4086.
These results suggest that iNOS inhibition may be protective
against some aspects of asthma but not others. The present
study represents a continuation of our effort to understand
the role of iNOS in asthma and explore new mechanisms by
which the enzyme can be targeted for therapy against the
disease. What is certain is that the enzyme plays important
roles in the disease; what is lacking, however, is the strategy by
which it can be adequately targeted to achieve an efficacious
clinical outcome. We believe that the results of the present
study renew the potential of iNOS as a therapeutic target for
asthma with a specific consideration to the levels of NO in
patients treated with selective iNOS inhibitors.
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Figure 4: Effects of PARP inhibition on iNOS expression in LPS/IFN-𝛾-treated MEFs and of iNOS inhibition on the protection conferred by
the PARP inhibitor olaparib against AHR in chronicallyHDM-exposedmice. (a)MEFs derived fromWTor PARP-1−/−micewere treatedwith
a combination of 1 𝜇g/mL LPS and 10 ng/mL IFN-𝛾. RNA was isolated after 6 hours of treatment and reverse-transcribed to generate cDNA,
which was subjected to quantitative PCR with primers specific to mouse iNOS or 𝛽-actin.The data is expressed as fold change normalized to
levels of 𝛽-actin. ∗ and ∗ ∗ ∗, difference from nonstimulated cells with 𝑝 ≤ 0.05 and 𝑝 ≤ 0.001, respectively; ###, difference from LPS/IFN-
𝛾-treated WT cells with 𝑝 ≤ 0.001. (b) WT mice were subjected to HDM sensitization followed by a chronic i.n. challenge with HDM or left
unchallenged. Challenged mice were administered i.p. 5mg/kg olaparib with or without 5mg/kg of L-NIL 30min after each HDM challenge.
Penh was recorded 24 h after the last challenge in response to increasing doses of MeCh. Results are plotted as maximal fold increase of Penh
relative to baseline and expressed asmean± SEM,where 𝑛 = 5mice per group.∗∗, difference fromHDMchallengedmice; ##, difference from
the group that received 5mg/kg olaparib; 𝑝 ≤ 0.01. RNA isolated from the lungs of the different experimental groups was reverse-transcribed
and the resulting cDNAwas subjected to real time PCR with primer sets specific to mouse IL-5 or 𝛽-actin. Data is expressed as fold change of
values detected in lungs of control mice. ∗∗, difference from control unchallenged mice; ##, difference from HDM-exposed mice receiving
olaparib; ns, no significant difference. Note that values of control and HDM-exposed mice are the same as those described for Figure 3(c).
High levels of iNOS and ONOO−, the reactive byproduct
of NO, are undoubtedly deleterious and participate in the
pathology of asthma [19, 27, 28] as well as many chronic
inflammatory diseases [9–12]. Sugiura et al. showed that
patients with refractory asthma have even higher levels of
iNOS and protein nitration in cells collected from their
sputum than those from patients with well-controlled asthma
[29]. This connection was recently strengthened by a study
demonstrating that an iNOS-Dual oxidase-2-thyroid per-
oxidase metabolome is the basis of nitrogen radicals and
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subsequent protein nitration in human severe asthma [30].
Our results show that the elevated iNOS expression is also
observed in PBMCs of asthmatics and potentially even
higher in cells from asthmatics with uncontrolled disease.
Surprisingly, this is the first report examining the levels of
iNOS and protein nitration in PBMCs of asthmatics. Our
results suggest that the role of iNOS in the pathogenesis
of the disease may stem from circulating cells in addition
to those in the lung. Although the cohort size is small in
the present study, our results show a potential disconnect
between expression of iNOS and protein nitration within
the same cells suggesting that PBMCs may not be the major
target of NO and its byproducts. This disconnect does not
appear to exist in cells derived from either bronchial lavage
fluids or sputum as shown by Yamamoto et al. and Sugiura
et al., respectively [13, 29]. Altogether, the results of these
studies and many others including ours [19, 20] predict that
iNOS may be an ideal target for the treatment of asthma.
Surprisingly, targeting this enzyme has been unsuccessful
[17]. We speculated that our understanding of the role of NO
and iNOS in asthma may not be sufficient to allow a better
approach to achieve the desirable clinical outcomes using
selective iNOS inhibitors.
In the current study, we show that iNOS inhibition, by
the selective inhibitor L-NIL and confirmed by the use of
a gene knockout approach, provided an excellent protection
against AHR upon an acute exposure but not upon a chronic
exposure to allergens in two experimental asthma models.
These results are rather similar to the differential protection
provided by iNOS inhibition against airway inflammation.
It is noteworthy that NO supplementation aggravated Th2
inflammation in HDM-exposed mice as assessed by lung
IL-5 mRNA levels. At this stage it is not clear whether
the protection and loss of protection in the acute and
chronic models, respectively, are associated with the status
of inflammation as manifestation of AHR is not always
strictly related to inflammation in human asthmatics [31].
The interesting aspect of this study is that the protection
was recovered in the chronic HDM asthma model after NO
supplementation by nitrite administration.The dose of nitrite
used in this study was shown to deliver low-to-moderate
levels of NO and protects against several oxidative stress-
related conditions including hypoxic vasodilation, ischemia
of the heart and liver, and postoperative ileus [26, 32, 33].
It is important to acknowledge that the failure of iNOS
inhibition to protect against AHR in chronic asthma may
be related to other factors besides NO; however, the level of
the gas may constitute a major determinant in the protection
against AHR. It is also important to acknowledge that one
of the limitations of the current study is that the levels of
NO upon nitrate supplementation were not measured. We
predict that these levels might not have reached those in
HDM-exposed mice; otherwise, we would expect a failure
of protection against AHR manifestation. An additional
limitation is the quantification of Penh using whole body
plethysmography to measure AHR. Although measuring
lung resistance is regarded as a better means to assess lung
function, our previous studies demonstrate, for instance, a
similar protection against AHR by PARP inhibitors using
either method [22, 34]. Additionally, Penh has been demon-
strated to correlate well with invasive measures of AHR
[35].
Our laboratory established a reciprocal relationship
between iNOS and PARP-1 [20]. PARP-1 activity and expres-
sion are required for iNOS expression [36]. Such regulation
is linked to the dependence of iNOS gene on NF-𝜅B and
control of the activity as well as the subcellular trafficking
of the transcription factor by PARP-1. Interestingly, PARP
inhibition, pharmacologically or by gene knockout, pro-
tected against inflammation and AHR both upon acute and
chronic exposures to either OVA or HDM. Such protection
occurred despite the fact that iNOS expression is markedly
reduced upon PARP inhibition. It is interesting, however,
that PARP-1 inhibition does not completely abrogate expres-
sion of iNOS. This partial inhibition may allow for only
low-to-moderate level production of NO and constitutes
the basis for the persistent protection against AHR con-
ferred by PARP inhibition even after a chronic exposure to
allergens.
5. Conclusions
Our results provide additional support for the hypothesis
that the amount of iNOS and NO are critical determinants
in the modulation of AHR by selective iNOS inhibitors and
may also help explain why the clinical study by Singh et al.
[17] found that GW274150 failed to protect against AHR. It
is noteworthy that the levels of exhaled NO achieved upon
administration of the inhibitor reached amounts lower than
those observed in healthy nonsmoker and nonatopic subjects
as comprehensively reviewed by Dweik et al. [37]. The severe
reduction in the levels of NO in the study by Singh et al.
may be detrimental and as such prevention of AHR might
not have been possible. Furthermore, the drug was delivered
orally, which may be another limitation of the study. These
speculations and the positive results of our study on the role of
iNOS and the critical influence of NO levels on AHR should
lead to reevaluation of the benefit of selective iNOS inhibitors
in blocking AHR in human asthmatics, especially those with
uncontrolled disease.
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Additional Points
The results of the present study suggest that the amount of
nitric oxide may be critical for the protection against airway
hyperresponsiveness and renew the potential of iNOS as a
therapeutic target for the treatment of asthma.
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